Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape

Published:2022-11-08 Issue:12 Volume:15 Page:1399-1413
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Uliano Jacopo¹²,Nicolò Eleonora¹²^ORCID,Corvaja Carla¹³^ORCID,Taurelli Salimbeni Beatrice¹⁴^ORCID,Trapani Dario¹⁵^ORCID,Curigliano Giuseppe¹²^ORCID

Affiliation:

1. Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy

2. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

3. Department of Medicine, University of Udine, Udine, Italy

4. Department of Clinical and Molecular Medicine, Oncology Unit, “La Sapienza” University of RomeAzienda Ospedaliera Sant’Andrea, Rome, Italy

5. Department of Medical Oncology, Medical Oncology Dana Farber Cancer Institute, Boston, MA, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2022.2142559

Reference115 articles.

1. LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

2. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

3. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

4. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

5. Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;Current Gene Therapy;2025-02

2. The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies;Cell Death & Disease;2024-06-19

3. Advancing Breast Cancer Drug Delivery: The Transformative Potential of Bioinformatics and Artificial Intelligence;Current Cancer Therapy Reviews;2024-03-13

4. Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities;Current Breast Cancer Reports;2023-06-29

5. Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management;Expert Review of Clinical Pharmacology;2023-05-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3